Brilique: Can AZ polish a third-to-market drug?
This article was originally published in Scrip
Executive Summary
Today's management upheaval at AstraZeneca underlines the desperate measures that CEO Pascal Soriot will need if he is to put the company on a sound footing. And the sorry story of one product – the oral antiplatelet Brilique/Brilinta – illustrates just how ineffective scrabbling around the fringes of drug commercialization can be.